Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

cts in clinical development or marketed products.

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. Currently our market capitalization is less than our book value. As a result, we may be required to take a significant non-cash goodwill impairment charge and may be required to write off goodwill or other intangible assets in the future. If we are required to write off goodwill or other intangible assets, our financial position or resu
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... Texas , May 30, 2015  Caris ... from a study in which researchers identified biomarker ... metachronous paired glioma tumors, indicating changes in response ... observing 19 patients was a subset of a ... molecular heterogeneity of the cancer. These data utilizing ...
(Date:5/29/2015)... , May 29, 2015 In recent years, ... availability of Big Data that can generate valuable insights. ... with utilizing Big Data have caused the biopharmaceutical sector ... industries. According to a recent study ... already have a Big Data team or function in ...
(Date:5/29/2015)... 29, 2015 GeneWEAVE, Inc ... (MDROs), announced that initial feasibility data supporting the ... and susceptibility testing from positive blood cultures will ... 31, 2015 in New Orleans, LA. The Company’s ... diagnostics that can quickly detect bacteria and assess ...
(Date:5/29/2015)... -- Asthma treatment could   see ... treatments enter arena, says   GBI Research ... several of the leading asthma brands, such as Advair ... the global market for asthma treatment is set to ...   New analysis from business intelligence provider ...
Breaking Biology Technology:Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3
... Supports Further ... Clinical Development of tgAAC94, BOSTON and SEATTLE, May ... news release earlier today, entitled,"Targeted Genetics Reports Additional Data From ... 1/2,clinical study of tgAAC94 in patients with inflammatory arthritis. Pervin,Anklesaria, ...
... the increasing,challenges to patent protection and new product ... grow their pipelines.,With the increasing merger and acquisition ... integration of assets to be key in obtaining,value ... Integration,Excellence: What Bio- Pharma Companies Need to Know." ...
... U.S. cancer conference, CHICAGO, May 30 ... field of molecular diagnostics, announced today that data,from ... test,will be presented at the American Society of ... that MammaPrint, a,prognostic test for breast cancer recurrence ...
Cached Biology Technology:Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 2Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 3Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 2MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions 2MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions 3MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions 4
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... KINGSTON, R.I. July 23, 2009 News reports ... by large numbers of Humboldt,s or jumbo squid have raised ... As a leading expert on the species who has ... and says the squid,s man-eating reputation is seriously overblown. ...
... study released online on July 22 in the journal ... researchers at Arizona State University and Princeton University show ... our multimodal, egg-headed, tool-using, bipedal, opposing-thumbed selves. ... "stupider" than ants. Humans and animals simply often make ...
... Texas Medical Branch at Galveston have identified women who are ... commonly known as Depo-Provera or the birth control shot. These ... will gain weight and will help physicians to counsel patients ... within the first six months of use, called "early gainers," ...
Cached Biology News:URI researcher sheds light on 'man-eating' squid; finds them timid, nonthreatening 2URI researcher sheds light on 'man-eating' squid; finds them timid, nonthreatening 3Ants more rational than humans 2UTMB study identifies women at risk of gaining excessive weight with injectable birth control 2
... Histone Deacetylase (HDAC) Antibody Sampler Kit ... (HDAC1) Antibody, Catalog #2062, 40 ul Histone ... ul Histone Deacetylase 4 (HDAC4) Antibody, Catalog ... Antibody, Catalog #2082, 40 ul Histone Deacetylase ...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
Request Info...
interferon-related developmental regulator 2...
Biology Products: